Skip to main content
Premium Trial:

Request an Annual Quote

AmoyDx, Sanomics Ink Deal for Multigene Mutation Detection Kit

NEW YORK (GenomeWeb) — Amoy Diagnostics has signed an agreement giving Sanomics the right to offer its multigene mutation detection kit in Hong Kong and Macau, the companies announced on Monday.

AmoyDx's kit is designed to detect 96 hotspot mutations/fusions in the EGFR, KRAS, BRAF, NRAS, HER2, PIK3CA, ALK, ROS1, and RET genes in tumor tissue to help guide treatment decisions for non-small cell lung cancer patients. It uses the firm's PCR-based ADx Amplification Refractory Mutation System technology and was approved by China's National Medical Products Administration in August.

According to the companies, Hong Kong-based Sanomics will offer the kit through its OncoSnap Nonet service. Additional terms of the deal were not disclosed.

About a year ago, Xiamen, China-based AmoyDx signed on Medikonia to distribute its molecular diagnostic tests in Hong Kong and Macau.

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.